: Figure S1. Cell type composition by sample type. Figure S2. The comparation of DMPs in high TMB or low TMB based on lung cancer type LUAD or LUSC in our cohort. Figure S3. The comparation of DMPs in
Background: Pyrotinib, an irreversible pan-ERBB inhibitor, has shown promising antitumour activity, and acceptable tolerability. This research was conducted to evaluate the actual use and effectivenes
Bulk TCR repertoire data and R code for "TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma"
